Calyx Chemicals and Pharmaceuticals is an API manufacturer based in India. It holds 18 active US drug master files across a filed portfolio of 15 molecules. Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 17 May 2024 as OAI. Customs aggregates show $3.7M of exports covering 72 molecules to 24 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| District Palghar, India | 3003721861 |
| Palghar, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Erythromycin | US FDA | 3 |
| Azithromycin | US FDA | 2 |
| Isoniazid | SFDA (Saudi Arabia), US FDA | 2 |
| Artemether | US FDA | 1 |
| Cetirizine | US FDA | 1 |
| Eszopiclone | US FDA | 1 |
| Flucytosine | US FDA | 1 |
| Hydroxyzine | US FDA | 1 |
| Irbesartan | US FDA | 1 |
| Losartan | US FDA | 1 |
| Lumefantrine | US FDA | 1 |
| Meclizine | US FDA | 1 |
| Pyrazinamide | US FDA | 1 |
| Valganciclovir | US FDA | 1 |
| Zopiclone | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 1 | None |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $1.1M | 8 |
| 2025 | Not reported | $3.7M | 24 |
| 2024 | Not reported | $2.7M | 24 |
| 2023 | Not reported | $2.0M | 18 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Calyx Chemicals and Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.